# Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction

> **NCT05445921** · PHASE1,PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 20 (actual)

## Conditions studied

- Anosmia
- Hyposmia
- Parosmia
- Olfactory Disorder

## Interventions

- **DRUG:** Stellate Ganglion Block

## Key facts

- **NCT ID:** NCT05445921
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2022-12-12
- **Final completion:** 2022-12-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445921, "Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05445921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*